Analysts predict that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce sales of $7.74 million for the current quarter, Zacks reports. Five analysts have provided estimates for Conatus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $14 million and the lowest estimate coming in at $3 million. The business is scheduled to report its next quarterly earnings results on Wednesday, August 2nd.
On average, analysts expect that Conatus Pharmaceuticals will report full-year sales of $7.74 million for the current financial year, with estimates ranging from $16 million to $40.09 million. For the next year, analysts expect that the company will post sales of $43.46 million per share, with estimates ranging from $4 million to $107.1 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.20. The firm had revenue of $7 million during the quarter, compared to analysts’ expectations of $5.88 million. During the same period in the prior year, the business earned ($0.35) earnings per share.
Several equities research analysts have recently commented on the company. Stifel Nicolaus restated a “buy” rating and issued a $9.00 price objective (up from $7.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, March 16th. FBR & Co restated an “outperform” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research note on Wednesday, March 15th. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 14th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Conatus Pharmaceuticals in a research note on Friday, March 17th. Finally, Aegis restated a “buy” rating and issued a $11.00 price objective on shares of Conatus Pharmaceuticals in a research note on Thursday, March 16th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Conatus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $13.25.
TRADEMARK VIOLATION WARNING: This story was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/05/19/5-88-million-in-sales-expected-for-conatus-pharmaceuticals-inc-cnat-this-quarter-updated-updated.html.
A number of hedge funds and other institutional investors have recently modified their holdings of CNAT. Courage Capital Management LLC purchased a new position in shares of Conatus Pharmaceuticals during the third quarter valued at $200,000. ING Groep NV purchased a new position in shares of Conatus Pharmaceuticals during the fourth quarter valued at $110,000. Renaissance Technologies LLC increased its position in shares of Conatus Pharmaceuticals by 193.5% in the fourth quarter. Renaissance Technologies LLC now owns 183,700 shares of the biotechnology company’s stock valued at $968,000 after buying an additional 121,100 shares in the last quarter. Ellington Management Group LLC purchased a new position in shares of Conatus Pharmaceuticals during the fourth quarter valued at $154,000. Finally, United Capital Financial Advisers LLC increased its position in shares of Conatus Pharmaceuticals by 5.7% in the fourth quarter. United Capital Financial Advisers LLC now owns 154,578 shares of the biotechnology company’s stock valued at $815,000 after buying an additional 8,369 shares in the last quarter. 15.90% of the stock is owned by institutional investors.
Conatus Pharmaceuticals (NASDAQ:CNAT) traded down 7.88% during mid-day trading on Friday, reaching $6.78. The company’s stock had a trading volume of 1,634,471 shares. The firm’s market cap is $177.43 million. The company has a 50-day moving average price of $6.52 and a 200-day moving average price of $4.31. Conatus Pharmaceuticals has a 12-month low of $1.45 and a 12-month high of $9.40.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.